Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

Author(s):: Vincent, L.; Gras, L.; Ceballos, P.; Finke, J.; Passweg, J.; Harel, S.; Rosinol, L.; Minnema, M.; Teipel, R.; Doesum, J. van; Hanel, M.; Lenain, P.; Botella-Garcia, C.; Koenecke, C.; Ducastelle, S.; Sanz, J.; Schroyens, W.; Zuckerman, T.; Monaco, F.; Koster, L.; Wreede, L. de; Hayden, P.J.; Schonland, S.; Yakoub-Agha, I.; Beksac, M.